CZ-415 is primarily used in research settings as a potent and selective agonist for the GPR40 receptor, also known as the free fatty acid receptor 1 (FFA1). Activation of GPR40 plays a role in glucose-dependent insulin secretion, making CZ-415 a compound of interest in the development of new treatments for type 2 diabetes. It helps enhance insulin release in response to elevated blood glucose levels without increasing the risk of hypoglycemia. Due to its high selectivity and efficacy in preclinical models, CZ-415 serves as a valuable tool for studying metabolic pathways and beta-cell function. It is not used clinically but supports drug discovery efforts targeting metabolic disorders.